Editorial to “The Japanese catheter ablation registry (J-AB): Annual report in 2022”

IF 2.2 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS
Germaine Loo MBBS, Chi Keong Ching MBBS, FHRS
{"title":"Editorial to “The Japanese catheter ablation registry (J-AB): Annual report in 2022”","authors":"Germaine Loo MBBS,&nbsp;Chi Keong Ching MBBS, FHRS","doi":"10.1002/joa3.13176","DOIUrl":null,"url":null,"abstract":"<p>In recent years, several nationwide registries for patients undergoing catheter ablation have been published.<span><sup>1</sup></span> This provides perspective on real-world practice, reporting in depth information on the current trends, efficacy, and safety data on catheter ablation. There is a rise in prevalence of atrial fibrillation and other arrhythmias, due to global ageing populations, increased patient comorbidities, and technological advancements in arrhythmia detection.<span><sup>2</sup></span> This translates to an increasing volume and trend of patients undergoing catheter ablation—most prominent for atrial fibrillation. Comparing data from the Japanese Catheter Ablation Registry (J-AB) from 2018 to 2022, there has been an increasing overall number and proportion of atrial fibrillation ablation cases: 40, 422 cases (72.8%) versus 68, 378 cases (75.9%), respectively.<span><sup>1</sup></span></p><p>The biggest strength of the J-AB registry lies in its numbers, recording the acute procedural characteristics and outcomes of a total of 90,042 cases, which is one of the largest reported nationwide registries to date. Knowing the ablation trends and volume would aid healthcare cost projection at both hospital and nationwide levels. In addition, this would serve as an important data repository for investigators to explore further regarding the mechanisms and treatment of arrhythmias.</p><p>Marked advancements in the field of catheter ablation over the past decades have led to improvements in durability and safety of catheter ablation.<span><sup>3</sup></span> The development and utilization of electro-anatomical mapping systems, novel catheters and energy sources for ablation, as well as innovative ablation strategies have revamped the catheter ablation landscape. Cryoablation ablation has showed high acute procedural success and lower incidence of procedural complications compared to radiofrequency ablation (RFA).<span><sup>3</sup></span> Despite this, looking at the current data from the J-AB 2022 registry, majority of pulmonary vein isolation (PVI) ablation were performed with RFA alone (72.7%), with the rest utilizing alternative techniques with or without concurrent RFA.</p><p>Pulsed field ablation (PFA), utilizing electric pulses to produce non-thermal irreversible electroporation and cell death, is emerging as a suitable alternative to achieve PVI. The penta-spline catheter design allows for rapid and efficient PVI, and the integration of PFA catheters with current 3-D electro-anatomical mapping systems can reduce fluoroscopy duration. Although prospective trials have validated the clinical efficacy of PFA, large randomized controlled trials comparing radiofrequency ablation to PFA are awaited.<span><sup>4</sup></span> We hypothesize that there will be a greater trend towards using PFA for PVI in the coming years and in turn increase the volume of AF ablation.</p><p>Results from the J-AB registry showed an acute procedural success rate of 99.6% for first time PVI for atrial fibrillation and 99.3% for cavo-tricuspid isthmus dependent atrial flutter. Acute overall complication rates from catheter ablation were low at 2.3%, with the most common being major bleeding complications at 0.9%. Mortality rate related to ablation therapy was less than 0.1%. This result is similar to that reported in other nationwide registries.<span><sup>1</sup></span> The reported rates serve as a benchmark for newer centers to assess their quality of catheter ablation. Perhaps what can be improved upon is the collection of procedural duration and fluoroscopic duration to further aid the evaluation of procedural safety for both patients and operators.</p><p>Finally, there are still many unanswered questions pertaining to catheter ablation. Additional information, such as ablation lesion sets beyond PVI in atrial fibrillation, ablation energy sources, utilitization of electroanatomical mapping system and intraprocedural imaging statistics will further enrich this registry. Similarly, long term outcome data regarding arrhythmia burden post ablation, usage of antiarrhythmic drugs, and anticoagulation therapy will add to its strength. These data may help bridge knowledge gaps in catheter ablation for management of arrythmias. Nevertheless, the J-AB registry serves a key role in providing a contemporary understanding in the trends and outcomes of Asian patients undergoing catheter ablation.</p><p>There are no conflict of interest for all authors.</p>","PeriodicalId":15174,"journal":{"name":"Journal of Arrhythmia","volume":"40 6","pages":"1357-1358"},"PeriodicalIF":2.2000,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11632249/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Arrhythmia","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/joa3.13176","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

In recent years, several nationwide registries for patients undergoing catheter ablation have been published.1 This provides perspective on real-world practice, reporting in depth information on the current trends, efficacy, and safety data on catheter ablation. There is a rise in prevalence of atrial fibrillation and other arrhythmias, due to global ageing populations, increased patient comorbidities, and technological advancements in arrhythmia detection.2 This translates to an increasing volume and trend of patients undergoing catheter ablation—most prominent for atrial fibrillation. Comparing data from the Japanese Catheter Ablation Registry (J-AB) from 2018 to 2022, there has been an increasing overall number and proportion of atrial fibrillation ablation cases: 40, 422 cases (72.8%) versus 68, 378 cases (75.9%), respectively.1

The biggest strength of the J-AB registry lies in its numbers, recording the acute procedural characteristics and outcomes of a total of 90,042 cases, which is one of the largest reported nationwide registries to date. Knowing the ablation trends and volume would aid healthcare cost projection at both hospital and nationwide levels. In addition, this would serve as an important data repository for investigators to explore further regarding the mechanisms and treatment of arrhythmias.

Marked advancements in the field of catheter ablation over the past decades have led to improvements in durability and safety of catheter ablation.3 The development and utilization of electro-anatomical mapping systems, novel catheters and energy sources for ablation, as well as innovative ablation strategies have revamped the catheter ablation landscape. Cryoablation ablation has showed high acute procedural success and lower incidence of procedural complications compared to radiofrequency ablation (RFA).3 Despite this, looking at the current data from the J-AB 2022 registry, majority of pulmonary vein isolation (PVI) ablation were performed with RFA alone (72.7%), with the rest utilizing alternative techniques with or without concurrent RFA.

Pulsed field ablation (PFA), utilizing electric pulses to produce non-thermal irreversible electroporation and cell death, is emerging as a suitable alternative to achieve PVI. The penta-spline catheter design allows for rapid and efficient PVI, and the integration of PFA catheters with current 3-D electro-anatomical mapping systems can reduce fluoroscopy duration. Although prospective trials have validated the clinical efficacy of PFA, large randomized controlled trials comparing radiofrequency ablation to PFA are awaited.4 We hypothesize that there will be a greater trend towards using PFA for PVI in the coming years and in turn increase the volume of AF ablation.

Results from the J-AB registry showed an acute procedural success rate of 99.6% for first time PVI for atrial fibrillation and 99.3% for cavo-tricuspid isthmus dependent atrial flutter. Acute overall complication rates from catheter ablation were low at 2.3%, with the most common being major bleeding complications at 0.9%. Mortality rate related to ablation therapy was less than 0.1%. This result is similar to that reported in other nationwide registries.1 The reported rates serve as a benchmark for newer centers to assess their quality of catheter ablation. Perhaps what can be improved upon is the collection of procedural duration and fluoroscopic duration to further aid the evaluation of procedural safety for both patients and operators.

Finally, there are still many unanswered questions pertaining to catheter ablation. Additional information, such as ablation lesion sets beyond PVI in atrial fibrillation, ablation energy sources, utilitization of electroanatomical mapping system and intraprocedural imaging statistics will further enrich this registry. Similarly, long term outcome data regarding arrhythmia burden post ablation, usage of antiarrhythmic drugs, and anticoagulation therapy will add to its strength. These data may help bridge knowledge gaps in catheter ablation for management of arrythmias. Nevertheless, the J-AB registry serves a key role in providing a contemporary understanding in the trends and outcomes of Asian patients undergoing catheter ablation.

There are no conflict of interest for all authors.

日本导管消融登记(J-AB)》的社论:2022 年年度报告 "的编辑。
近年来,一些全国性的导管消融患者登记已经公布这提供了现实世界实践的视角,深入报道了导管消融的当前趋势、疗效和安全性数据。由于全球人口老龄化、患者合并症增加以及心律失常检测技术的进步,房颤和其他心律失常的患病率有所上升这意味着接受导管消融的患者数量和趋势都在增加,最突出的是房颤。对比2018年至2022年日本导管消融登记处(J-AB)的数据,房颤消融病例的总数和比例均有所增加:分别为40422例(72.8%)和68378例(75.9%)。J-AB登记的最大优势在于其数量,共记录了90,042例的急性程序特征和结果,这是迄今为止报道的最大的全国登记之一。了解消融术的趋势和数量将有助于医院和全国范围内的医疗成本预测。此外,这将为研究人员进一步探索心律失常的机制和治疗提供重要的数据库。在过去的几十年里,导管消融领域取得了显著的进步,这使得导管消融的耐久性和安全性得到了提高电解剖定位系统、新型导管和消融能源的开发和利用,以及创新的消融策略,已经改变了导管消融的格局。与射频消融(RFA)相比,冷冻消融具有较高的急性手术成功率和较低的手术并发症发生率尽管如此,从J-AB 2022登记的当前数据来看,大多数肺静脉隔离(PVI)消融是单独使用RFA进行的(72.7%),其余的使用有或没有RFA的替代技术。脉冲场烧蚀(PFA)利用电脉冲产生非热不可逆电穿孔和细胞死亡,是实现PVI的合适替代方案。五样条导管设计允许快速和有效的PVI, PFA导管与当前的3-D电解剖测绘系统的集成可以减少透视时间。虽然前瞻性试验已经证实了PFA的临床疗效,但将射频消融与PFA进行比较的大型随机对照试验仍在等待中我们推测,在未来几年,PFA治疗PVI的趋势将会更大,从而增加房颤消融的体积。J-AB登记的结果显示,首次PVI治疗心房颤动的急性手术成功率为99.6%,对于腔-三尖瓣峡部依赖性心房扑动的急性手术成功率为99.3%。导管消融的急性总并发症发生率较低,为2.3%,最常见的是大出血并发症,为0.9%。消融治疗相关死亡率小于0.1%。这一结果与其他全国性登记报告的结果相似报告的比率可作为新中心评估其导管消融质量的基准。也许可以改进的是收集手术持续时间和透视持续时间,以进一步帮助评估患者和操作人员的手术安全性。最后,关于导管消融仍有许多未解决的问题。其他信息,如房颤PVI以外的消融病变集、消融能量来源、电解剖制图系统的利用和术中成像统计将进一步丰富该登记。同样,关于消融后心律失常负担、抗心律失常药物使用和抗凝治疗的长期结果数据将增加其强度。这些数据可能有助于弥合导管消融治疗心律失常方面的知识差距。尽管如此,J-AB注册在提供亚洲患者导管消融趋势和结果的当代理解方面发挥了关键作用。所有作者都不存在利益冲突。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Arrhythmia
Journal of Arrhythmia CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
2.90
自引率
10.00%
发文量
127
审稿时长
45 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信